Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors Meeting Abstract
| Authors: | Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Martinez, E. J.; Makker, V.; Canziani, L.; Teruel, C. F.; Soto-Matos, A.; Sessa, C.; Calvo, E. |
| Abstract Title: | Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi125 |
| Language: | English |
| ACCESSION: | WOS:000393912500389 |
| DOI: | 10.1093/annonc/mdw368.34 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 391P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
